80 SUBSEQUENT MYELODYSPLASTIC SYNDROMES IN PROSTATE CANCER PATIENTS AFTER RADIOTHERAPY, A POPULATION-BASED STUDYBackground: Blood products, supportive care, and hypomethylating agents (HMAs) are frequently used to improve outcomes of patients with MDS, and they may incur substantial costs. It is ...
After an initial period of tumor regression, prostate cancers become unresponsive to these therapies and eventually progress to the “castrate-resistant” state. Currently, there is no curative treatment available for castrate-resistant prostate cancer, and chemotherapy has limited benefits in improving ...
Sexual function may diminish after the diagnosis of prostate cancer and its treatment,11 and recall of past levels of sexual activity among individuals with prostate cancer could be distorted as a consequence of prostate malignancy or ongoing therapy....
Afterskin cancer, prostatecanceris the most commoncancerin men and in people assigned male a birth. About 1 in 8 will be diagnosed with prostate cancer in their lifetime. And these are just the ones who are diagnosed. Among very elderly men who die of other causes, a surprising two-third...
Prostate cancer is usually a very slow-growingcancer, often causing no symptoms until it is in an advanced stage. Most men with prostatecancerdie of other causes and many never know that they have the disease. But once prostatecancerbegins to grow quickly or spreads outside the prostate, it...
Genetic testing, to identify pathogenic or likely pathogenic variants in prostate cancer, is valuable in guiding treatment decisions for men with prostate cancer and to inform cancer prevention and early detection options for their immediate blood relati
Nearly one-third of patients with prostate cancer (PCa) experience biochemical recurrence (BCR) after primary definitive treatment. BCR increases the risk of distant metastasis and mortality in patients with prognostically unfavorable features. These patients are best managed with a tailored treatment str...
The current approach to prostate cancer diagnosis in the UK and many other HICs relies on "informed choice" PSA testing, meaning men aged 50 or over with no symptoms can request the test from their doctor after a discussion of the risks and benefits. ...
The role of steroid hormones in carcinogenesis of the prostate is to some extent unraveled thorough the effect of androgen deprivation therapy on prostate cancer (PCa) progression. Other members of the steroid hormone family, such as progesterone, are also implicated in PCa, but progesterone’s rol...
FULL PAPER British Journal of Cancer (2013) 108, 1784–1789 | doi: 10.1038/bjc.2013.181 Keywords: prostate cancer; side effects; toxicity; health-related quality of life; prostatectomy; radiotherapy Quality of life after prostate cancer treatments in patients comparable at baseline J J van Tol-...